Emcure will exclusively distribute and promote Sanofi’s OAD range of products that include brands like Amaryl and Cetapin. Sanofi will continue to own and manufacture these brands across its plants in India and internationally. Emcure will engage healthcare professionals and expand reach of the therapeutic solutions across India, according to a statement.
There will be no people transition from Sanofi India to Emcure in this arrangement.
Emcure’s presence across India will help Sanofi tap into the full growth potential of its oral anti-diabetic, said Eric Mansion, general manager-pharma, Southeast Asia and India at Sanofi.
“With our strong distribution network in India, Sanofi’s oral anti-diabetic medicines will be available to more patients who need them,” said SatishMehta, CEO and MD at Emcure. “This collaboration complements our existing diabetes portfolio.”
